Yi 2015.

Methods	Study design: Randomised clinical trial Study duration: January 2009 to January 2011 Duration of follow‐up: 3 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by images; tumour number < 4; maximal tumour diameter ≤ 10 cm; Karnofsky score ≥ 70; with liver function of Child‐Pugh Class A or B Exclusion criteria: With history of other tumours; with extrahepatic metastasis; with inferior vena cava or portal vein tumour thrombus Age (mean ± SD): TACE + RFA: 52.14 ± 7.46 years; TACE alone: 51.98 ± 7.28 years Male (n/total): TACE + RFA: 35/49; TACE alone: 35/48 Child‐Pugh Class (patients): Class A: TACE + RFA: 32; TACE: 33 Class B: TACE + RFA: 17; TACE: 15
Interventions	TACE + RFA group (n = 49): TACE: Chemotherapeutic drugs: mitomycin and adriamycin RFA: The interval between TACE and RFA was 2 weeks. 10‐15 minutes per RFA session, ablation margin of 1 cm TACE group (n = 48): Chemotherapeutic drugs: mitomycin and adriamycin
Outcomes	Tumour response, according to WHO criteria Adverse events 1‐, 2‐, and 3‐year survival rates
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.